- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02177279
Bioactive Phytochemicals From Wheat Bran (WB2001)
Identification of Novel Bioactive Compounds in Wheat Bran
There is a lot of evidence to suggest that eating a diet rich in cereals such as wheat bran are beneficial in protecting us from diseases such as heart disease, diabetes and cancer. It is still not clear exactly why this happens, but it is likely that the compounds which enter our bodies when we eat such products are responsible. In this study we plan to find out what these compounds are and where they are found. The investigators will do this by asking volunteers to eat a wheat-bran meal and then measuring the compounds that appear in blood, urine and stool samples over the next twenty-four hours. Once the investigators know how much and which compounds are present, we can then find out possible reasons why they are protective, for example by looking to see whether they are anti-inflammatory. We also plan to look at whether if having a diet which contains either a lot of wheat-bran products or very low amounts of these foods effects how they are absorbed by the body.
HYPOTHESIS: Wheat bran from ready-to-eat cereal has unique phytochemical profiles which are metabolized to compounds responsible for high cellular bioactivity imparting important health benefits.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Aberdeenshire
-
Aberdeen, Aberdeenshire, United Kingdom, AB21 9SB
- Rowett Institute of Nutrition and Health, University of Aberdeen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Volunteers will be healthy males or females and aged between 18 and 55 years who have a documented low (less than 1 portion per week) or high (more than or equal 5 portions per week) consumption of wheat bran and are able to give informed consent.
Exclusion Criteria:
- are taking any medicines prescribed by their general practitioner
- are taking drugs to lower high cholesterol levels or high blood pressure
- regularly take analgesics, antipyretic or anti-inflammatories
- regularly take nutritional supplements
- have taken antibiotics in the last three months
- have given a large blood donation in last three months
Study Plan
How is the study designed?
Design Details
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Visit A- 120g wheat bran cereals
A morning vist where volunteers consumed 120g of wheat bran cereals with 125ml semi-skimmed milk
|
|
Other: Visit B-40g wheat bran cereals
A morning vist where volunteers consumed 40g of wheat bran cereals with 375 ml semi-skimmed milk
|
|
Other: Follow up-40g (8days), 120g (1day) wheat bran cereals
Volunteers follow their normal diet but they were asked to consume 40g wheat bran cereals with 125 ml semi-skimmed milk for eight days and on day nine 120g wheat bran cereals with 375ml semi-skimmed milk
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Human bioavailability of benzoic acids and derivatives from wheat bran cereals
Time Frame: over 24 h
|
The analysis of the benzoic acid and derivatives metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24 h
|
Human bioavailability of cinnamic acids and derivatives from wheat bran cereals
Time Frame: over 24h
|
The analysis of the cinnamic acids and derivatives metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24h
|
Human bioavailability of phenylpropanoid dimers from wheat bran cereals
Time Frame: over 24h
|
The analysis of the phenylpropanoid dimers metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24h
|
Human bioavailability of phenyl propionic acids from wheat bran cereals
Time Frame: over 24h
|
The analysis of the phenyl propionic acids metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24h
|
Bioavailability of benzaldehydes from wheat bran
Time Frame: over 24h
|
The analysis of the benzaldehydes metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24h
|
Human bioavailability of acetophenones from wheat bran cereals
Time Frame: over 24h
|
The analysis of the acetophenones metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24h
|
Human bioavailability of lignans from wheat bran cereals
Time Frame: over 24 h
|
The analysis of the lignans metabolites in blood, urine, faecal samples after consumption of 40g and 120g wheat bran cereals, over 24 h period (change from baseline time 0h).
|
over 24 h
|
Short chain fatty acids profile after wheat bran consumption (acute)
Time Frame: 24 h
|
Short chain fatty acids profile in faecal samples at 0h (baseline) and 24h after wheat bran consumption (40g and 120g).
|
24 h
|
Short chain fatty acids profile after wheat bran consumption (chronic)
Time Frame: 9 days
|
Short chain fatty acids profile in in faecal samples at day 0 (baseline), day 5 (during 7 days consumption of 40g wheat bran cereals/day) and day 10 (after 120g wheat bran cereals consumption on day 9).
|
9 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Wendy R Russell, PhD, Rowett Institute of Nutrition and Health, University of Aberdeen
- Principal Investigator: Baukje de Roos, PhD, Rowett Institute of Nutrition and Health, University of Aberdeen
- Principal Investigator: Garry Duthie, Professor, Rowett Institute of Nutrition and Health, University of Aberdeen
- Principal Investigator: Jolene McMonagle, PhD, Kellogg Company
- Principal Investigator: Reg Fletcher, PhD, Kellogg Company
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- Wheat Bran 2001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Visit A high wheat bran
-
KU LeuvenCompleted
-
University of FloridaKellogg's Corporate Citizens FundCompletedEndocrine, Nutritional, Metabolic and Immunity DisordersUnited States
-
Kellogg CompanyTufts University; University of Toronto; University of Saskatchewan; University... and other collaboratorsCompleted
-
Purdue UniversityCompletedObesity | Diabetes Mellitus, Type 2 | Appetitive BehaviorUnited States
-
Fugeia NVCompletedHealthy Subjects | Gastrointestinal HealthBelgium
-
Glycemic Index Laboratories, IncUniversity of Toronto; University of Guelph; University of Sydney; Agriculture... and other collaboratorsCompletedHypercholesterolemiaCanada, Australia, United Kingdom
-
Maastricht University Medical CenterCompletedObesity | Change of Transit or Circulation
-
Fugeia NVCompleted
-
Agricultural University of AthensCompletedAppetitive Behavior | Potential Abnormality of Glucose ToleranceGreece
-
University of Eastern FinlandVTT Technical Research Centre of FinlandCompletedGlucose Metabolism Disorders | Inflammation | Intestinal Disorder